HIV Prevention Product Overview

Product	Yearly Dosage	Frequency, Volume, Delivery Site, Drug Class	Efficacy, Efficacy Date	Developer, Regulatory, Generics	LMIC Price PPPY
Oral PrEP (TDF/FTC) (TDF/xTC) (F/TAF)		One pill **every day**; event-driven dosing of 2-1-1 for cisgender men (TDF/FTC only) TDF/FTC: Oral tablet-200mg FTC, 300mg TDF F/TAF: Oral tablet - 200mg FTC, 25mg TAF Nucleoside reverse transcriptase inhibitor (NRTI)	High ↑ **TDF/FTC - 2010** All populations (±90% with 7 doses/week); highly adherent-dependent High ↑ **F/TAF - 2019** Cisgender men & TG women (±90% with 7 doses/week); highly adherent-dependent	Gilead Sciences >100 approvals WHO recommended in 2015 15+ suppliers globally	±$40
Dapivirine Vaginal Ring (DVR)		One ring **every month** One 25mg dapivirine vaginal ring Non-nucleoside reverse transcriptase inhibitor (NNRTI)	Moderate ↑ **DVR - 2016** Cisgender women (35% risk reduction in efficacy trials; 50%+ reduction with consistent use in Open Label Extension studies; highly adherent-dependent	IPM / PopCouncil 11 approvals WHO recommended in 2021 MOU with Kiara in South Africa; license and timelines TBD	$71
Injectable Cabotegravir (CAB)		First injection on day 1, second injection 1 month later, then **every 2 months** One 3 mL intramuscular injection in gluteal muscle (buttocks) Integrase strand transfer inhibitor (INSTI)	Very High ↑ **CAB - 2020** All populations (89% higher effectiveness in cisgender women and 66% in MSM and TG women, compared to oral PrEP)	Viiv Healthcare 30 approvals WHO recommended in 2022 3 licenses via MPP, expected earliest market access in 2027	≅$160 (set in GBP; USD subject to currency fluctuations)
Injectable Lenacapavir (LEN)		First injection and two oral tablets on day 1, two oral tablets on day 2, then injections **every 6 months** Two 1.5 mL subcutaneous injections in abdomen and four 300mg lenacapavir tablets Capsid inhibitor	Very High ↑ **LEN - 2024** All populations (100% efficacy in cisgender women, 96% reduction compared to background HIV incidence in cisgender men and TG and GNB people)	Gilead Sciences 17 approvals WHO recommended in 2025 6 direct licenses, market access in Q4 2026	Originator price not public, assumed $100. Generic price (2027) $40 PPPY plus $15-17 for oral loading dose

LMIC = low- and middle-income country; PPPY = per person per year; TG = transgender; MSM = men who have sex with men; GNB = gender nonbinary

AVAC
Advocacy. Access. Equity.

November 2026